StockDocs
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
DRMA

Dermata Therapeutics, Inc.

DRMAW Nasdaq Pharmaceutical Preparations EDGAR ↗
$0.01
+0.00 0.00%

Key statistics

from XBRL data in SEC filings
Market cap
$30.2K
Revenue (TTM)
Net income (TTM)
-$7.10M
EPS (TTM)
$-4.17
P/E ratio
Dividend yield
Free cash flow
Cash
$6.95M
Total assets
$7.47M
Gross margin
52-week range
$0.01 – $0.01

Recent SEC filings

40 most recent
Annual, quarterly & current reports
8-K Director or officer change; Shareholder vote results May 27, 2026 10-Q Quarter ended 2026-03-31 May 13, 2026 8-K Results of operations (earnings release) May 13, 2026 10-K Fiscal year ended 2025-12-31 Mar 26, 2026 8-K Results of operations (earnings release) Mar 26, 2026 8-K Director or officer change Feb 25, 2026 8-K Changed accountants Feb 3, 2026 8-K Other events Jan 27, 2026 8-K Entered a material agreement; Unregistered sale of equity; Other events Dec 29, 2025 8-K Terminated a material agreement Nov 18, 2025 10-Q Quarter ended 2025-09-30 Nov 14, 2025 8-K Results of operations (earnings release); Regulation FD disclosure Nov 14, 2025 8-K Other events Nov 7, 2025 8-K Other events Sep 17, 2025 8-K Other events Sep 10, 2025 8-K Other events Aug 25, 2025 10-Q Quarter ended 2025-06-30 Aug 13, 2025 8-K Results of operations (earnings release); Regulation FD disclosure Aug 13, 2025 8-K Modified rights of security holders; Amended charter or bylaws Jul 30, 2025 8-K Shareholder vote results Jul 16, 2025 8-K Delisting notice or listing-rule failure Jul 7, 2025 8-K Changed accountants Jun 5, 2025 8-K Regulation FD disclosure; Other events May 21, 2025 8-K Delisting notice or listing-rule failure May 16, 2025 8-K Results of operations (earnings release); Regulation FD disclosure May 14, 2025 10-Q Quarter ended 2025-03-31 May 14, 2025 8-K Regulation FD disclosure; Other events Apr 15, 2025 8-K Entered a material agreement; Unregistered sale of equity; Modified rights of security holders Mar 28, 2025 8-K Regulation FD disclosure; Other events Mar 27, 2025 8-K Delisting notice or listing-rule failure Mar 25, 2025 8-K Results of operations (earnings release); Regulation FD disclosure Mar 17, 2025 10-K Fiscal year ended 2024-12-31 Mar 17, 2025 8-K Entered a material agreement; Unregistered sale of equity; Other events Jan 23, 2025 8-K Entered a material agreement; Regulation FD disclosure Jan 21, 2025 8-K Results of operations (earnings release); Regulation FD disclosure Nov 14, 2024 10-Q Quarter ended 2024-09-30 Nov 13, 2024 8-K Entered a material agreement; Unregistered sale of equity; Other events Sep 17, 2024 8-K Results of operations (earnings release); Regulation FD disclosure Aug 7, 2024 10-Q Quarter ended 2024-06-30 Aug 7, 2024 8-K Other events Aug 2, 2024